Search research articles
Contact Us
Filters
Showing results (241-250 of 252) with videos related to
Page
of 26
Sort By:
Medrxiv : the Preprint Server for Health Sciences
|
April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial
Angela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Journal of Infectious Diseases
|
April 29, 2025
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
Robert L Atmar, Kirsten E Lyke, Christine M Posavad, et al.
The Journal of Infectious Diseases
|
August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
Nadine G Rouphael, Angela R Branche, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 21, 2021
Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report
Robert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
The New England Journal of Medicine
|
January 26, 2022
Homologous and Heterologous Covid-19 Booster Vaccinations
Robert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
Cell Reports. Medicine
|
July 7, 2022
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Kirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
NPJ Vaccines
|
July 11, 2023
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Kirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Youyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine
|
February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances
Fei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Nature Communications
|
January 17, 2025
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Bo Zhang, Youyi Fong, Lauren Dang, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 252) with videos related to
Sort By:
Page
of 26
Medrxiv : the Preprint Server for Health Sciences
|
April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial
Angela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Journal of Infectious Diseases
|
April 29, 2025
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
Robert L Atmar, Kirsten E Lyke, Christine M Posavad, et al.
The Journal of Infectious Diseases
|
August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
Nadine G Rouphael, Angela R Branche, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 21, 2021
Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report
Robert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
The New England Journal of Medicine
|
January 26, 2022
Homologous and Heterologous Covid-19 Booster Vaccinations
Robert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
Cell Reports. Medicine
|
July 7, 2022
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Kirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
NPJ Vaccines
|
July 11, 2023
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Kirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Youyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine
|
February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances
Fei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Nature Communications
|
January 17, 2025
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Bo Zhang, Youyi Fong, Lauren Dang, et al.
Page
of 26